Enalare Therapeutics
Princeton, US · Founded 2018 · Delaware corporation
Enalare Therapeutics is a clinical-stage biopharmaceutical company developing therapies for patients with acute respiratory conditions. It works to advance its drug products through development, regulatory review, and launch.
Founders & leadership
GS
Gino SantiniNamed on SEC filing
JP
Joseph PergolizziNamed on SEC filing
HC
Herman CukierNamed on SEC filing
JP
Joseph PetkoNamed on SEC filing
DM
Daniel MottoNamed on SEC filing
RY
Robert YedidNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$13.5M disclosed across 2 of 3 rounds · 2020–2022
▶$12.5MraisedAug 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$12.5MraisedAug 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert YedidDirector
- Mark ColemanDirector
- Daniel MottoExecutive Officer
- Joseph PergolizziExecutive Officer, Director
- Gino SantiniDirector
- Joseph PetkoDirector
- Herman CukierExecutive Officer, Director
- Offering amount
- $55M
- Amount sold
- $12.5M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$1MraisedFeb 2022 · 12 investors · PharmaceuticalsRule 506(b)
▶$1MraisedFeb 2022 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gino SantiniDirector
- Daniel MottoExecutive Officer
- Robert YedidDirector
- Mark ColemanDirector
- Joseph PergolizziExecutive Officer, Director
- Herman CukierExecutive Officer, Director
- Joseph PetkoDirector
- Offering amount
- $10M
- Amount sold
- $1M
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$10MofferedDec 2020 · PharmaceuticalsRule 506(b)
▶$10MofferedDec 2020 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gino SantiniDirector
- Joseph PergolizziExecutive Officer, Director
- Herman CukierExecutive Officer, Director
- Joseph PetkoDirector
- Daniel MottoExecutive Officer
- Robert YedidDirector
- Offering amount
- $10M
- Proceeds to insiders
- $1.4M
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapAro Biotherapeutics6 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Adarepharmasolutions5 shared keywordsAdare Pharma Solutions is a contract development and manufacturing organization (CDMO) that develops and produces specialized oral-dose and injectable drug delivery systems at cGMP-compliant global manufacturing sites. It also provides in-house regulatory affairs support to help pharmaceutical clients bring products from molecule to market.
Bioworld5 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Enalare Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $319.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Enalare Therapeutics do?
- Enalare Therapeutics is a clinical-stage biopharmaceutical company developing therapies for patients with acute respiratory conditions. It works to advance its drug products through development, regulatory review, and launch.
- How much funding has Enalare Therapeutics raised?
- Enalare Therapeutics has disclosed $13.5M raised across 2 of its 3 known rounds.
- Where is Enalare Therapeutics headquartered?
- Enalare Therapeutics is headquartered in Princeton, US.